PDS Biotechnology (FRA:EU6) Beta: 2.4811 (As of Jun. 25, 2026)


FRA:EU6 PDS Biotechnology Corp FRA:EU6
31 GF Score
Price €0.77
! 1 Warning Sign
View Full Analysis

What is PDS Biotechnology Beta?

PDS Biotechnology FRA:EU6 -3.50% 31 Beta is 2.4811 as of Jun. 25, 2026. GuruFocus rates FRA:EU6 with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), PDS Biotechnology's Beta is 2.4811.


PDS Biotechnology  (FRA:EU6) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


PDS Biotechnology Beta Related Terms


PDS Biotechnology Beta Historical Data

* Premium members only.

The historical data trend for PDS Biotechnology's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PDS Biotechnology Beta Chart

PDS Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.01 2.95 2.47 0.20 -0.25

PDS Biotechnology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.43 1.23 0.93 -0.25 0.15

FRA:EU6 vs INKT, PMVP, EDSA: Beta Comparison

For the Biotechnology subindustry, PDS Biotechnology's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PDS Biotechnology Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's Beta distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's Beta falls into.


FRA:EU6
31GF Score
PDS Biotechnology Corp FRA:EU6
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PDS Biotechnology Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.4811 mean?
PDS Biotechnology (FRA:EU6) has a Beta of 2.4811 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for PDS Biotechnology and its competitors.
Is PDS Biotechnology's Beta too high?
PDS Biotechnology's current Beta is 2.4811. Overall, PDS Biotechnology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does PDS Biotechnology's Beta compare to INKT and PMVP?
PDS Biotechnology's Beta of 2.4811 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for PDS Biotechnology and its competitors. PDS Biotechnology's current Beta is 2.4811. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PDS Biotechnology stock overvalued right now?
PDS Biotechnology (FRA:EU6) has a current Beta of 2.4811. The current Beta is 2.4811. PDS Biotechnology's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For PDS Biotechnology (FRA:EU6), the current Beta is 2.4811 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PDS Biotechnology Business Description

Other Exchanges PDSB:USA
Address 303A College Road, East Princeton, NJ, USA, 08540
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
31GF Score

Get the complete analysis for FRA:EU6

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price